Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.21
-0.08 (-0.97%)
Mar 9, 2026, 1:32 PM EDT - Market open
Emergent BioSolutions Revenue
In the year 2025, Emergent BioSolutions had annual revenue of $742.90M, down -28.81%. Emergent BioSolutions had revenue of $148.70M in the quarter ending December 31, 2025, a decrease of -23.63%.
Revenue (ttm)
$742.90M
Revenue Growth
-28.81%
P/S Ratio
0.57
Revenue / Employee
$825,444
Employees
900
Market Cap
425.04M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 742.90M | -300.70M | -28.81% |
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 303.80M |
| Evolus | 297.18M |
| Ironwood Pharmaceuticals | 296.15M |
| Akebia Therapeutics | 236.20M |
| Canopy Growth | 203.04M |
| Kamada | 174.79M |
| SIGA Technologies | 172.25M |
EBS News
- 6 days ago - Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors - GlobeNewsWire
- 9 days ago - Emergent BioSolutions Earnings: Revenue, Margins, And GAAP Losses Paint A Mixed Picture - Seeking Alpha
- 10 days ago - Emergent BioSolutions Inc. (EBS) Q4 2025 Earnings Call Prepared Remarks Transcript - Seeking Alpha
- 10 days ago - Emergent BioSolutions Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 10 days ago - Emergent BioSolutions Announces Approximately $140 Million in Contract Awards with the Government of Canada, Strengthening Canada's Leadership in Health Preparedness - GlobeNewsWire
- 10 days ago - Emergent BioSolutions Announces New $50 Million Stock Repurchase Program - GlobeNewsWire
- 24 days ago - Emergent BioSolutions Receives U.S. FDA Approval of Supplemental New Drug Application (sNDA) for NARCAN® Nasal Spray Multipacks - GlobeNewsWire
- 25 days ago - Emergent BioSolutions to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 - GlobeNewsWire